Insight Molecular Diagnostics Inc. — Director's Dealing 2025

Feb 10, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2025-02-06

Reporting Person: BROADWOOD PARTNERS, L.P. (10% Owner)
Reporting Person: BROADWOOD CAPITAL INC (10% Owner)
Reporting Person: BRADSHER NEAL C (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-06	Common Stock, no par value	P	660207	$2.05	Acquired	6904612	Direct
2025-02-06	Common Stock, no par value	P	0	—	Acquired	6904612	Indirect
2025-02-06	Common Stock, no par value	P	4505488	$2.05	Acquired	11410100	Direct
2025-02-06	Common Stock, no par value	P	0	—	Acquired	11410100	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	157	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant to Purchase Common Stock	$30.60	2027-04-19	Common Stock (150093)	150093	Direct
Warrant to Purchase Common Stock	$30.60	2027-04-19	Common Stock (150093)	150093	Indirect

Footnotes

F1: The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: These securities are directly owned by Neal C. Bradsher.

F3: On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 660,207 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a registered direct offering for a total purchase price of $1,353,424, or $2.05 per Common Share.

F4: On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with the Issuer pursuant to which Broadwood Partners agreed to acquire 4,505,488 shares of Common Shares, from the Issuer in a private placement for a total purchase price of $9,236,250, or $2.05 per Common Share.

F5: These warrants are currently exercisable.